Notice of intended sale
Open the filing on sec.gov
Keros Therapeutics, Inc. (KROS)
Nasdaq: KROS · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2016
The companyfiscal 2025, as filed
Revenue$244M+6775.0%
Net income$87.0M+146.4%
Earnings per share$2.30+146.0%
Operating cash flow$108M+166.8%
Cash$289M-48.5%
Debtn/a
Shareholders’ equity$303M-47.0%
Shares, diluted37.9M+1.1%
Return on equity28.7%
The recordfrom its filings
Filings in 202683
Newest filingNov 12 · 144
Annual reportMar 4, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$500,000
Insider buys, 12 months$100,000
Patents granted15
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $40.8MNet income -$61.7MCash from operations -$47.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Current report
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Form DEL AM
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.